In 2023, hospital discharges for chronic diseases of tonsils and adenoids in Germany were higher than 63.2 per 100,000 persons. From 2024, a downward trend is visible with forecasted discharges decreasing year-on-year: 10.6% in 2025, 11.7% in 2026, 12.8% in 2027, and 14.7% in 2028. The compound annual growth rate (CAGR) reflects an average yearly decline over the five years leading from 2024 through 2028.
Future trends to watch for include:
- The impact of advancements in treatment and preventative care for chronic diseases of tonsils and adenoids on hospital discharges.
- Improved public health initiatives and awareness campaigns potentially leading to earlier detection and non-surgical interventions.
Latest reports
US Autoimmune Disease Market Report- Q1 2025
The US autoimmune disease market in Q1 2025 is experiencing significant shifts driven by advancements in biosimilars, biologics, and innovative therapies. The focus...
China Autoimmune Disease Market Report- Q1 2025
The autoimmune disease market in China has experienced substantial growth in the first quarter of 2025, driven by significant advancements in biopharmaceutical developments,...
Japan Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 witnessed significant developments in the autoimmune disease market in Japan, driven by technological advancements and strategic collaborations that...
Germany Autoimmune Disease Market Report- Q4 2024
The fourth quarter of 2024 marked a significant period for the autoimmune disease market in Germany, driven by advancements in treatment options and...
UK Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 has seen significant developments in the Autoimmune Disease UK market, driven by advancements in personalized medicine, increasing prevalence...
South Korea Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 marks a pivotal period for the Autoimmune Disease Market in South Korea, characterized by significant economic, technological, and...
